Digital Twin in Oncology Market Revenue to Attain USD 7226.9 Mn by 2035

Published: 18 Feb 2026

Author: Precedence Research

Share:

Digital Twin in Oncology Market Revenue and Trends 2026 to 2035

The global digital twin in oncology market revenue was valued at USD 450.00 million in 2025 and is expected to attain around USD 7226.9 million by 2035, growing at a CAGR of 32.00% during forecast period.The market's growth is driven by the increasing incidence of cancer, a growing emphasis on personalized oncology care, and rapid technological progress.

What are the Factors Contributing to the Growth of the Digital Twin in Oncology Market?

The increasing use of digital twins in clinical trials and drug development is the major driver, accelerating the growth of the market. The rising adoption of digital twins develops synthetic control arms and simulates virtual trials that reduce the cost associated with traditional drug development. Digital twins (DTs) are revolutionizing cancer care by offering dynamic virtual, patient-specific replicas. Oncologists are increasingly using digital twins to simulate treatment responses, survival outcomes, and disease trajectories in real time. By integrating multi-omics data (transcriptomics, genomics, proteomics, metabolomics), imaging, and lifestyle factors, digital twins enable evaluation of different therapeutic strategies before bedside decisions. The market's growth is also largely driven by rapid advancements in real-time tumor simulation and monitoring, which enhance treatment outcomes.

Segment Insights

• By component, the software platforms segment accounted for the highest revenue share of nearly 79% in 2025, owing to its computational and analytical capabilities in generating actionable treatment plans from fragmented data.
• By type, the patient digital twins segment contributed the biggest revenue share of nearly 44.5% in the market in 2025. The growth of the segment is driven by the ability to simulate patient-specific tumor responses to develop therapies that minimize side effects. Digital Patient Twins integrate physiological, biological, and behavioral data to simulate patient-specific treatment effects
• By application, the personalized medicine segment registered its dominance over the global market with a share of nearly 36% in 2025. Digital twins are rapidly advancing personalized oncology care by providing tailored insights and optimizing treatment outcomes.
• By end user, the hospitals & clinics segment held the largest revenue share of nearly 39.5% in the market in 2025, owing to rising demand for patient-specific modelling for personalized medicine and operational efficiency tools. Hospitals & clinics have advanced infrastructure and access to large volumes of patient data. Digital twins assist healthcare professionals in simulating tumor behavior, personalizing therapy plans, and predicting drug responses.

Regional Insights

North America holds the dominant share in the global digital twin in oncology market. The region’s leadership is driven by the owing to its presence of sophisticated healthcare infrastructure, early technology adoption, mature AI ecosystems, the growing demand for precision treatment, rapid technological advancement, the increasing burden of cancer, significant R&D investments, growing adoption of AI-powered patient simulation models, and a surge in government funding.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the rising investments in advanced healthcare infrastructure, the rise in R&D investments, the increasing prevalence of cancer, and the growing demand for personalized therapies. Moreover, the rising investment in the expansion of smart hospital infrastructure and favorable government initiatives promoting healthcare digitalization for cancer treatment are expected to accelerate the market’s growth in the coming years.

Digital Twin in Oncology Market Coverage

Recent Developments

• In October 2025, SOPHiA GENETICS, a leader in AI-driven precision medicine, announced the launch of SOPHiA DDM Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.  SOPHiA DDM Digital Twins uses each patient's unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease.(Source: https://www.prnewswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7707 

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344